Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

11.93USD
7:09pm BST
Change (% chg)

$-0.21 (-1.73%)
Prev Close
$12.14
Open
$12.20
Day's High
$12.36
Day's Low
$11.86
Volume
54,201
Avg. Vol
99,338
52-wk High
$14.62
52-wk Low
$6.60

Chart for

About

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR,... (more)

Overall

Beta: --
Market Cap(Mil.): $763.12
Shares Outstanding(Mil.): 93.52
Dividend: --
Yield (%): --

Financials

  ADAP.OQ Industry Sector
P/E (TTM): -- 86.20 32.69
EPS (TTM): -1.00 -- --
ROI: -32.06 0.73 14.32
ROE: -35.60 1.82 16.04

BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04

* ADAPTIMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

09 May 2018

Earnings vs. Estimates